BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen‐activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: We have previously shown that heat shock protein (Hsp) 27 or its upstream activator p38 mitogen‐activated protein kinase (MAPK) confers resistance to bortezomib and dexamethasone (Dex) in multiple myeloma (MM) cells. This study examined anti‐MM activity of a novel p38 MAPK inhibitor, BIRB 796, alone and in combination with conventional and novel therapeutic agents. BIRB 796 blocked baseline and bortezomib‐triggered upregulation of p38 MAPK and Hsp27 phosphorylation, thereby enhancing cytotoxicity and caspase activation. The Hsp90 inhibitor 17‐allylamino‐17‐demethoxy‐geldanamycin (17‐AAG) upregulated protein expression and phosphorylation of Hsp27; conversely, BIRB 796 inhibited this phosphorylation and enhanced 17‐AAG‐induced cytotoxicity. Importantly, BIRB 796 inhibited Hsp27 phosphorylation induced by 17‐AAG plus bortezomib, thereby enhancing cytotoxicity. In bone marrow stromal cells (BMSC), BIRB 796 inhibited phosphorylation of p38 MAPK and secretion of interleukin‐6 (IL‐6) and vascular endothelial growth factor triggered by either tumour necrosis factor‐α or tumour growth factor‐β 1. BIRB 796 also inhibited IL‐6 secretion induced in BMSCs by adherence to MM cells, thereby inhibiting tumour cell proliferation. These studies therefore suggest that BIRB 796 overcomes drug‐resistance in the BM microenvironment, providing the framework for clinical trials of a p38 MAPK inhibitor, alone and in combination with bortezomib, Hsp90 inhibitor, or Dex, to improve patient outcome in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Mitogen-activated protein kinases in apoptosis regulation
Wada, T., & Penninger, J. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207556 · Cited by 1,432
On the role of Hsp27 in regulating apoptosis
Concannon, C. G., Gorman, A. M., & Samali, A. (2003) · Apoptosis · doi:10.1023/a:1021601103096 · Cited by 513 · cited 1×
“…in MM cells (Mitsiades et al, 2002, 2006); and Hsp’s inhibit apoptotic signalling at several levels (Jolly & Morimoto, 2000; Xanthoudakis & Nicholson, 2000; Concannon et al, 2003), pharmacological inhibition of Hsp’s in bortezomib-treated MM cells might enhance apoptosis (Mitsiades et al, 2006).”
BackgroundAlsayed, Y., Uddin, S., Mahmud, N., Lekmine, F., Kalvakolanu, D. V., Minucci, S., Bokoch, G., & Platanias, L. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007431200 · Cited by 161 · cited 2×
“Inhibition of p38 MAPK using SB203580 enhanced growth inhibition triggered by ATRA or arsenic trioxide.”
BackgroundHayashi, T., Hideshima, T., Nguyen, A. N., Munoz, O., Podar, K., Hamasaki, M., Ishitsuka, K., Yasui, H., Richardson, P., Chakravarty, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0632 · Cited by 110 · cited 2×
“…in BMSCs triggered by TGF-b1, which modulates production of IL-6 and VEGF, ª 2006 The Authors 420 Journal Compilation ª 2006 Blackwell Publishing Ltd, British Journal of Haematology, 136, 414–423 thereby conferring MM cell growth in the BM microenvironment (Hayashi et al, 2004; Yasui et al, 2006).”
BackgroundSelf-citation
Cited by
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer
Yong, H.-Y., Koh, M.-S., & Moon, A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903321490 · Cited by 422
“BIRB-796 Cancer In vitro: Paracrine tumor cell Inhibition of IL-6 secretion and proliferation [78]”
BackgroundCampbell, R. M., Anderson, B. D., Brooks, N. A., Brooks, H. B., Chan, E. M., De Dios, A., Gilmour, R., Graff, J. R., Jambrina, E., Mader, M., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0513 · Cited by 121
“In multiple myeloma, p38 MAPK inhibitors down-regulate IL-6 secretion by bone marrow stromal cells (BMSCs), inhibit myeloma cell proliferation (23-26), and reduce osteoclastic bone destruction (24, 27).”
BackgroundFabre, C., Mimura, N., Bobb, K., Kong, S.-Y., Gorgun, G., Cirstea, D., Hu, Y., Minami, J., Ohguchi, H., Zhang, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0779 · Cited by 82
Self-citation
Metadata
- Authors
- Yasui, H., Hideshima, T., Ikeda, H., Jin, J., Ocio, E. M., Kiziltepe, T., Okawa, Y., Vallet, S., Podar, K., Ishitsuka, K., Richardson, P. G., Pargellis, C., Moss, N., Raje, N., & Anderson, K. C.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2006-12-14
- Volume
- 136
- Issue
- 3
- Pages
- 414-423
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2057770752
- Cited by
- 60
- References
- 5
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen‐activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. https://app.cochat.ai/papers/10.1111/j.1365-2141.2006.06443.x
- The paper
- Yasui, H., Hideshima, T., Ikeda, H., Jin, J., Ocio, E. M., Kiziltepe, T., Okawa, Y., Vallet, S., Podar, K., Ishitsuka, K., Richardson, P. G., Pargellis, C., Moss, N., Raje, N., & Anderson, K. C. (2007). BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen‐activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2006.06443.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.